159 related articles for article (PubMed ID: 38758815)
21. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE
Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.
Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802
[TBL] [Abstract][Full Text] [Related]
23. Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress.
Chua V; Lopez-Anton M; Mizue Terai ; Ryota Tanaka ; Baqai U; Purwin TJ; Haj JI; Waltrich FJ; Trachtenberg I; Luo K; Tudi R; Jeon A; Han A; Chervoneva I; Davies MA; Aguirre-Ghiso JA; Sato T; Aplin AE
Sci Signal; 2024 Jun; 17(840):eadn8376. PubMed ID: 38861613
[TBL] [Abstract][Full Text] [Related]
24. The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.
Chua V; Han A; Bechtel N; Purwin TJ; Hunter E; Liao C; Harbour JW; Aplin AE
Pigment Cell Melanoma Res; 2022 Jan; 35(1):78-87. PubMed ID: 34347929
[TBL] [Abstract][Full Text] [Related]
25. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers.
Kuznetsov JN; Aguero TH; Owens DA; Kurtenbach S; Field MG; Durante MA; Rodriguez DA; King ML; Harbour JW
Sci Adv; 2019 Sep; 5(9):eaax1738. PubMed ID: 31555735
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.
Ewens KG; Lalonde E; Richards-Yutz J; Shields CL; Ganguly A
BMC Cancer; 2018 Nov; 18(1):1172. PubMed ID: 30477459
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of GZ17-6.02 resistance.
Booth L; West C; Von Hoff D; Dent P
Anticancer Drugs; 2022 Jun; 33(5):415-423. PubMed ID: 35276694
[TBL] [Abstract][Full Text] [Related]
28. BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma.
Shah AA; Bourne TD; Murali R
Pathology; 2013 Dec; 45(7):651-6. PubMed ID: 24247622
[TBL] [Abstract][Full Text] [Related]
29. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.
Amirouchene-Angelozzi N; Nemati F; Gentien D; Nicolas A; Dumont A; Carita G; Camonis J; Desjardins L; Cassoux N; Piperno-Neumann S; Mariani P; Sastre X; Decaudin D; Roman-Roman S
Mol Oncol; 2014 Dec; 8(8):1508-20. PubMed ID: 24994677
[TBL] [Abstract][Full Text] [Related]
30. Germline large deletion of BAP1 and decreased expression in non-tumor choroid in uveal melanoma patients with high risk for inherited cancer.
Boru G; Grosel TW; Pilarski R; Stautberg M; Massengill JB; Jeter J; Singh A; Marino MJ; McElroy JP; Davidorf FH; Cebulla CM; Abdel-Rahman MH
Genes Chromosomes Cancer; 2019 Sep; 58(9):650-656. PubMed ID: 30883995
[TBL] [Abstract][Full Text] [Related]
31. HDAC Inhibition Enhances the
Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
[TBL] [Abstract][Full Text] [Related]
32. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
[TBL] [Abstract][Full Text] [Related]
33. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.
Abdel-Rahman MH; Pilarski R; Cebulla CM; Massengill JB; Christopher BN; Boru G; Hovland P; Davidorf FH
J Med Genet; 2011 Dec; 48(12):856-9. PubMed ID: 21941004
[TBL] [Abstract][Full Text] [Related]
34. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
35. BAP1 regulates cell cycle progression through E2F1 target genes and mediates transcriptional silencing via H2A monoubiquitination in uveal melanoma cells.
Pan H; Jia R; Zhang L; Xu S; Wu Q; Song X; Zhang H; Ge S; Xu XL; Fan X
Int J Biochem Cell Biol; 2015 Mar; 60():176-84. PubMed ID: 25582751
[TBL] [Abstract][Full Text] [Related]
36. Estimation of the timing of BAP1 mutation in uveal melanoma progression.
Uner OE; See TRO; Szalai E; Grossniklaus HE; Stålhammar G
Sci Rep; 2021 Apr; 11(1):8923. PubMed ID: 33903674
[TBL] [Abstract][Full Text] [Related]
37. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
38. Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma.
Yen M; Qi Z; Chen X; Cooper JA; Mitra RD; Onken MD
BMC Med Genomics; 2018 Nov; 11(1):97. PubMed ID: 30400891
[TBL] [Abstract][Full Text] [Related]
39. GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.
Moore AR; Ran L; Guan Y; Sher JJ; Hitchman TD; Zhang JQ; Hwang C; Walzak EG; Shoushtari AN; Monette S; Murali R; Wiesner T; Griewank KG; Chi P; Chen Y
Cell Rep; 2018 Feb; 22(9):2455-2468. PubMed ID: 29490280
[TBL] [Abstract][Full Text] [Related]
40. Correlation of Immunocytochemistry of BRCA1-associated Protein-1 (BAP1) With Other Prognostic Markers in Uveal Melanoma.
Glasgow BJ; McCannel TA
Am J Ophthalmol; 2018 May; 189():122-126. PubMed ID: 29530782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
